Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Research & Clinical Trials > Study Search Tool > Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

| More

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

This study is open to:

Patients are eligible if they:

  • have inoperable pancreatic cancer
  • are on platinum-based chemotherapy or have completed 16 weeks of platinum therapy previously
  • ave not had evidence of tumor growth while on platinum therapy
  • have one of these mutations 
    • BRCA1
    • BRCA2
    • PALB2
  • are on treatment with platinum-based (cisplatin, oxaliplatin or carboplatin) treatment for locally advanced or metastatic pancreatic cancer and have received a minimum of 16 weeks of therapy without evidence of disease progression based on the investigator's opinion

This study is not open to:

Patients are not eligible if they:

  • received prior PARP inhibitor treatment
  • are resistance to platinum agents
  • are symptomatic from or have untreated CNS metastases
  • have a life expectancy of <12 weeks as determined by the investigator
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Maintenance Rucaparib for Pancreatic Cancer That Hasn't Progressed on Platinum Therapy in BRCA or PALB2 Mutation Carriers

Clinicaltrials.gov identifier:
NCT03140670

Treatment:
Pancreatic

Study Contact Information

Contact: Colleen Redlinger 215-220-9693 or email 

About the Study

This is a phase II clinical trial enrolling people with advanced (inoperable) pancreatic cancer who have a BRCA1, BRCA2 or PALB2 mutation to determine whether the PARP inhibitor, rucaparib, could be used as a maintenance therapy after at least 4 months of chemotherapy.

We will enroll patients who have received at least 4 months of platinum-based therapy such as FOLFIRINOX, FOLFOX or cisplatin + gemcitabine.  Patients will stop chemotherapy and will all start rucaparib, a pill that is taken twice a day. 

Type of Study

  • Single arm maintenance study
    • The study only has one treatment arm. This means that all patients who enroll in the trial will receive the study medication, rucaparib.
  • The study is a maintenance study. 
    • Maintenance treatments are given after a period of “induction” chemotherapy.  Currently, experts do not know if giving rucaparib as maintenance treatment after chemotherapy will improve survival or outcomes for patients with pancreatic cancer. 

What the Study Entails

  • Patients need to have a confirmed mutation in BRCA1, BRCA2 or PALB2.  This mutation can be in the germline (ie from a blood or saliva test) or in the tumor. Only patients with one of these three mutations may participate in the trial.
  • Patients must have had at least 4 months of treatment with chemotherapy that contains a platinum medication (oxaliplatin, cisplatin or carboplatin) without evidence that their cancer has grown while receiving platinum therapy.
  • Patients do not have to be receiving platinum chemotherapy at time of study entry, as long as they have previously had at least 4 months of this treatment.
  • Every patient will receive the oral PARP inhibitor, rucaparib

Study Schema

  1. STEP ONE: Patients who:

    • Have inoperable pancreatic cancer

    • Are on platinum-based chemotherapy or have completed 16 weeks of platinum therapy previously

    • Have not had evidence of tumor growth while on platinum therapy

    • Have a BRCA1, BRCA2 or PALB2 mutation

  2. STEP TWO:  

    • Start the study medication, rucaparib 

Study Lead Investigator

Kim Reiss Binder, MD
Abramson Cancer Center of the University of Pennsylvania 

Study Site 

Philadelphia, PA
Abramson Cancer Center of the University of Pennsylvania 

FORCE:Facing Our Risk of Cancer Empowered